NCT02064309进行中（未招募）1 期
An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 4
- 试验地点
- 2
- 主要终点
- Safety of device, as evaluated by incidence of adverse events or serious adverse events judged probable or highly probable related to the device
研究概览
简要总结
The primary objective of this clinical investigation is to investigate the safety of implantation of the human islet containing device Beta-Air in type 1 diabetic subjects.
The secondary objective of this clinical investigation is to investigate if the transplantation of macro-encapsulated human islets within the Beta-Air device can provide improved glycaemic control in type 1 diabetes patients with reduced incidences of hypoglycaemic episodes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent obtained before any investigation-related activities. Investigation-related activities are any procedure that would not have been performed during normal management of the subject.
- •Diagnosis of type 1 diabetes mellitus for > 5 years
- •Men or women > 18 years of age at the time of enrolment
- •Involvement in intensive diabetes management defined as self-monitoring of blood glucose level no less than a mean of three times per day averaged over each week and by the administration of three or more insulin injections per day or insulin pump therapy. This management must be under the direction of a diabetologist or diabetes specialist during the 12 months prior to study enrolment.
排除标准
- •Body mass index (BMI) > 30 kg/m²
- •Insulin requirement of > 1.0 Units/kg/day
- •HbA1c > 10 % (DCCT)
- •Random C-peptide > 0.003 nmol/l
- •Known untreated active proliferative diabetic retinopathy changes or increasing macular oedema
- •Renal failure (Glomerular Filtration Rate <60 ml/min)
- •Women of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or unwilling to use adequate contraceptive methods for the duration of the trial (implants, injectables, combined oral contraceptives, hormonal intrauterine device, sexual abstinence or vasectomised partner).
- •Active infection including hepatitis B, hepatitis C, HIV, Tbc
- •Any history of malignancy except for completely resected squamous or basal cell carcinoma of the skin
- •Known active alcohol or drug abuse.
- •Any coagulopathy or medical condition that would require long-term anticoagulant therapy (e.g., Warfarin) after transplantation (low-dose aspirin treatment is allowed) or subjects with an international normalized ratio (INR) > 1.
- •Severe co-existing cardiac disease, characterized by any of these conditions:
- •Recent myocardial infarction (within past 36 weeks)
- •Evidence of ischemia on functional cardiac exam within the last year
- •Left ventricular ejection fraction < 30 %
- •Cardiovascular conditions within 36 weeks prior to this trial:
- •i. Decompensated heart failure New York Heart Association (NYHA) class III or IV ii. Unstable angina pectoris iii. Coronary arterial bypass graft iv. Coronary angioplasty
- •Inadequately treated blood pressure elevation (systolic BP > 160 mmHg or diastolic blood pressure > 100 mmHg)
- •Use of any medications to treat diabetes other than insulin within 4 weeks of enrolment
- •Administration of live attenuated vaccine(s) within 8 weeks of enrolment
- •Any previous organ transplant
- •Treatment with any immunosuppressive drug
- •Any medical condition that, in the opinion of the investigator, will interfere with safe participation in the trial (e.g., systemic glucocorticoids)
- •Known or suspected allergy of hypersensitivity to trial product(s) or related products
- •The receipt of any investigational product within 30 days of screening for this trial
- •Any scheduled transplant in addition to the islet transplantation
- •Fulfillment of criteria for clinical pancreas or islet transplantation
研究组 & 干预措施
Human islets in Beta-Air device
Experimental
干预措施: Beta-Air device for encapsulation of transplanted human islets (Device)
结局指标
主要结局
Safety of device, as evaluated by incidence of adverse events or serious adverse events judged probable or highly probable related to the device
时间窗: 0-365 days
次要结局
- 3. Signs of immunization in transplanted patients.(0-365 days)
- 2. Incidence and severity of fibrosis surrounding the device during course of study.(0-365 days)
- 6. Numbers of patients with peak c-peptide >0.20 nmol/l, in response to the mixed meal tolerance test at 12 and 26 weeks post-transplantation(12 and 26 weeks post-transplantation)
- 1. Incidence of local or systemic inflammation or infection, incl. C-reactive protein rise, judged related to the device during course of study.(0-365 days)
- 7. C-peptide area under the curve in response to the mixed meal tolerance test at 12 and 26 weeks post-transplantation.(12 and 26 weeks post-transplantation)
- 5. Survival of endocrine tissue in the device, as evaluated by [11C]-5-hydroxytryptophane positron emission tomography and histological analysis at 26 weeks post-transplantation.(0-180 days)
- 8. Number of patients with non-fasting c-peptide concentrations >0.003 nmol/l at 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 and 26 weeks post-transplantation; i.e. Kaplan-Meier analysis of survival time for islet grafts.(0-26 weeks)
- 4. Oxygenation of tissue in the device, as evaluated at 4, 12 and 26 weeks post-transplantation(0-180 days)
研究者
Per-Ola Carlsson
Professor
Uppsala University Hospital
研究点 (2)
Loading locations...
相似试验
撤回
1 期
An Investigator-initiated Study to Evaluate Safety and Efficacy of ARINA-1 in People With a TracheostomyTracheostomyNCT05658029Matthew Bruehl
招募中
早期 1 期
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC PatientsAdvanced Hepatocellular CarcinomaNCT06418659Shanghai Changzheng Hospital37
招募中
早期 1 期
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC PatientsIntrahepatic CholangiocarcinomaNCT06583993Shanghai Changzheng Hospital9
已完成
1 期
Study on the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 Injection in Adult Patients With Atrial FibrillationAtrial FibrillationNCT06280768Beijing Suncadia Pharmaceuticals Co., Ltd10
招募中
1 期
Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors PatientsAdvanced or Metastatic Solid TumorsNCT05848466Bio-Thera Solutions109